Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sibrotuzumab

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
A prolonged state of left ventricular pressure overload, commonly caused by hypertension and aortic valve disease, promotes… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2017
2017
FBROBLAST ACTIVATION PROTEIN AND MMUNOCONUGATES CONTAINING THEMI
  • 2017
    • Corpus ID: 55568613
EP O953639 A1 11, 1999 EP 1258255 A1 11, 2002 WO 99.57151 A2 11/1999 WO O1687.08 A2 9, 2001 WO 02083171 10, 2002 WO 2005060999 A2… Expand
  • figure 5
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2006
2006
Molecular characterization of sarcomatous change in a granulosa cell tumor
Sarcomatous transformation of a granulosa cell tumor (GCT) is a rare event. We describe the development of a rapidly progressive… Expand
Highly Cited
2004
Highly Cited
2004
Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients
Population pharmacokinetics of sibrotuzumab, a humanized monoclonal antibody directed against fibroblast activation protein, were… Expand
Highly Cited
2003
Highly Cited
2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
PURPOSE The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2003
Highly Cited
2003
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
Background: A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein… Expand
  • table 1
  • table 2
  • figure 1
2003
2003
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1
Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2003
2003
Cancer Res . , 9 : 1639 Metastatic Fibroblast Activation Protein-positive Cancer . Study of Sibrotuzumab in Patients with Advanced or Dose-EscalationCommentary re : A .
 
  • figure 1
Highly Cited
2003
Highly Cited
2003
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation…
  • J. Cheng, L. Weiner
  • Clinical cancer research : an official journal of…
  • 2003
    • Corpus ID: 43635359
The conventional concept of tumor-host interactions is rooted in the realm of parasitology. A tumor invades an unsuspecting host… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE